Deltex Med Grp PLC DEMG Enhanced Recovery Update

  Deltex Med Grp PLC (DEMG) - Enhanced Recovery Update

RNS Number : 0403P
Deltex Medical Group PLC
19 October 2012


                           Deltex Medical Group plc


                           Enhanced recovery update

19 October 2012 - Deltex Medical  Group plc, the global leader in  oesophageal 
Doppler monitoring ("ODM"), announces further progress in establishing ODM  as 
a key element of enhanced recovery programmes for major surgery.

At the inauguralERAS Congress in Cannes,  France, 250 doctors from around  the 
world met to discuss the content, implementation and clinical effectiveness of
enhanced recovery. The importance of  fluid management during surgery and  ODM 
were recurring themes highlighted by speakers.

The Enhanced  Recovery  After  Surgery  ('ERAS')  academic  society  has  been 
expanded to include surgeons and  anaesthetists from Sweden, the  Netherlands, 
Norway, UK, Spain, Germany, Canada and  USA. In a further endorsement of  ODM, 
ERAS has  this  month published  clinical  guidelines for  rectal  and  pelvic 
surgery^1  which  include  a  "strong"  recommendation  in  respect  of  fluid 

"Fluid balance should be optimised by targeting cardiac output and avoiding
overhydration. Judicious use of vasopressors is recommended with arterial
hypotension. Targeted fluid therapy using the oesophageal Doppler system is

In a further development, doctors from Duke University in North Carolina,  who 
are members of ERAS, were  amongst speakers at a  reception on the subject  of 
enhanced recovery  held  at  the  British  Embassy  at  Washington  DC,  which 
coincided   with   the   annual   meeting   of   the   American   Society   of 
Anesthesiologists. The  100  guests  included  healthcare  policy  makers  and 
providers as  well as  doctors from  leading US  hospitals. The  presentations 
covered progress with  the UK  NHS roll-out  of enhanced  recovery across  all 
major surgical disciplines as  well as a report  on Duke's initial  experience 
within  colorectal   surgery.  The   Duke  programme   evidenced   significant 
enhancements, including fewer post operative complications, increased  patient 
satisfaction, a 40% reduction in hospital  stay and estimated cost savings  to 
the hospital of over 20%.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"There is  considerable momentum  behind the  spread of  enhanced recovery  as 
standard of  care  for  all  major  surgery in  Europe,  as  well  as  growing 
recognition of the opportunity to improve significantly surgical care  through 
its adoption in North America. ERAS is well positioned to set global  clinical 
standards  for   enhanced  recovery   and  it   is  encouraging   that   their 
recommendations highlight specifically ODM  technology. ODM is unique  amongst 
intra-operative  fluid  management   monitoring  technologies   in  having   a 
substantial evidence base demonstrating its benefits."

^1 Guidelines for Perioperative Care in Elective Rectal/Pelvic Surgery:
Enhanced Recovery After Surgery (ERAS) Society Recommendations. J Nygren, J
Thacker,F Carli,KCH. Fearon,S Norderval,DN Lobo,O Ljungqvist, M Soop,J
Ramirez. World Journal of Surgery October 2012

For further information, please contact:-

Deltex Medical Group plc 01243 774 837

Nigel Keen, Chairman

Ewan Phillips, Chief Executive

Paul Mitchell, Finance Director

Nominated Adviser & Broker

Arden Partners plc  020 7614 5900

Chris Hardie

Kreab Gavin Anderson 020 7074 1800

Robert        Speed

Deborah                Walter

Notes for Editors

Deltex Medical manufactures and  markets the CardioQ-ODMÔ system.  CardioQ-ODM 
changes the way doctors  care for surgical patients  allowing them to  recover 
faster and leave  hospital sooner  and in  better health  than they  otherwise 
would  do.  The  performance  of   the  system  has  been  validated   through 
independently conducted, randomised  controlled clinical trials  and is  being 
translated into  routine clinical  practice in  leading hospitals  around  the 

CardioQ-ODM comprises a monitor and a single patient disposable probe. The
probe is placed into the oesophagus through either the mouth or nose and the
tip positioned facing the adjacent descending aorta. A low frequency
ultrasound signal, generated by the monitor, is bounced off the blood
travelling down the aorta and the Doppler principle is used to determine the
velocity of the blood flow, expressed in distance per cardiac cycle - 'Stroke
Distance'. The monitor also calculates the amount of time that blood is
flowing down the aorta as a proportion of a cardiac cycle - 'Flow Time'.

The monitor uses a validated proprietary nomogram to extrapolate volumetric
data (Stroke Volume, Cardiac Output etc) from the directly measured flow
velocity. The nomogram utilises the patient's age weight and height,
effectively to estimate the size of the aorta in which the velocity of the
flow is being measured. Crucially this means that any reported relative change
in Stroke Volume is absolutely identical to the relative change in the
directly measured flow velocity variable of Stroke Distance. CardioQ-ODM
immediately and reliably identifies even very small changes in the blood flow
velocity allowing doctors to intevene earlier and on smaller changes than with
any other approach.

Intra-operative individualised Doppler guided fluid management entails
insertion and focusing of the probe to obtain a baseline reading, giving a
small (200 to 250 ml) fluid challenge directly into the vascular system and
seeing if Stroke Volume (or Stroke Distance) increases by more than 10%. If
the increase is more than 10%, repeat fluid boluses are administered until
such time as the increase is less than 10%: after this no further fluid is
given unless Stroke Volume falls by more than 10% - the process is designed to
achieve and maintain the individual patient's optimal Stroke Volume.
CardioQ-ODM is also used during surgery to guide administration of vaso-active
agents such as inotropes.

The CardioQ-ODM helps patients by enabling doctors to reduce the complications
that arise from  a medical  condition that is  common to  almost all  patients 
having surgery and many others in  intensive care or arriving in the  accident 
and emergency  department.  This  condition  is  known  as  hypovolaemia  -  a 
reduction in circulating blood volume -  and in surgical patients arises as  a 
direct consequence of  the combined effects  of pre-operative starvation,  the 
anaesthetic agents and the blood and fluid losses associated with the surgical
procedure itself. Hypovolaemia means that the body struggles to get sufficient
blood to  the tissues  and  vital organs  which  are consequently  starved  of 
essential oxygen. This  can cause medical  complications including  peripheral 
and major organ failure, which  if not dealt with  quickly can lead to  severe 
compromise or even death.

There are  already  over 2,500  CardioQ-ODMs  currently in  use  in  hospitals 
worldwide and distribution arrangements are in place in over 30 countries.  In 
addition, there are currently more than  250 clinical publications on the  use 
of the CardioQ-ODM which have repeatedly:-

·  Validated  the  results  of  CardioQ-ODM  against  known  standards  for 
measuring cardiac output

· Proved that CardioQ-ODM works in a wide range of surgical procedures

· Proved that CardioQ-ODM delivers 50% or more reductions in post-operative
complications and 25% or  more reductions in length  of hospital stay:  better 
care at lower cost.

The SupraQÔis an entirely non-invasive  device which uses an ultrasound  probe 
held at the  base of  the patient's neck  to track  the flow of  blood in  the 
aorta; it presents the same data as the CardioQ-ODM in a similar format and is
used for taking snapshots or monitoring over short periods.

                     This information is provided by RNS
           The company news service from the London Stock Exchange


NRABKFDBPBDDPKD -0- Oct/19/2012 06:00 GMT
Press spacebar to pause and continue. Press esc to stop.